Bordon AF, Kaiser PK, Wolf A, Cen L, et al. EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study. Retina 2024;44:1704-1713.
PMID: 39287533